IMMUNITYBIO, INC. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
IMMUNITYBIO, INC. (IBRX) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$230.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-04
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$230.56M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$634.30M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$38.00M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$74.84M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$323.71M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$412.46M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$584.02M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$417.14M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$230.56M 10-Q · filed 2026-08-04 | -$864.86M 10-Q · filed 2026-08-04 | -$902.86M derived: sum of 3 quarters · filed 2026-08-04 | -$977.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$634.30M 10-Q · filed 2026-05-07 | -$672.30M derived: sum of 2 quarters · filed 2026-05-07 | -$747.14M derived: sum of 3 quarters · filed 2026-05-07 | -$847.11M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$112.84M derived: sum of 2 quarters · filed 2026-02-23 | -$212.81M derived: sum of 3 quarters · filed 2026-08-04 | -$323.71M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$74.84M 10-Q · filed 2025-11-05 | -$174.81M derived: sum of 2 quarters · filed 2026-08-04 | -$285.71M 10-Q · filed 2025-11-05 | -$343.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$99.96M 10-Q · filed 2026-08-04 | -$210.87M 10-Q · filed 2026-08-04 | -$268.95M derived: sum of 3 quarters · filed 2026-08-04 | -$354.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$110.91M 10-Q · filed 2026-05-07 | -$168.99M derived: sum of 2 quarters · filed 2026-05-07 | -$254.63M derived: sum of 3 quarters · filed 2026-05-07 | -$389.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$58.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$143.72M derived: sum of 2 quarters · filed 2026-02-23 | -$278.31M derived: sum of 3 quarters · filed 2026-02-23 | -$412.46M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$85.64M 10-Q · filed 2025-11-05 | -$220.23M derived: sum of 2 quarters · filed 2025-11-05 | -$354.37M 10-Q · filed 2025-11-05 | -$588.57M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$134.59M 10-Q · filed 2025-08-05 | -$268.73M 10-Q · filed 2025-08-05 | -$502.93M derived: sum of 3 quarters · filed 2026-02-23 | -$597.74M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$134.15M 10-Q · filed 2025-05-12 | -$368.34M derived: sum of 2 quarters · filed 2026-02-23 | -$463.15M derived: sum of 3 quarters · filed 2026-02-23 | -$601.37M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$234.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$329.01M derived: sum of 2 quarters · filed 2026-02-23 | -$467.23M derived: sum of 3 quarters · filed 2026-02-23 | -$584.02M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$94.81M 10-Q · filed 2024-11-12 | -$233.03M derived: sum of 2 quarters · filed 2024-11-12 | -$349.83M 10-Q · filed 2024-11-12 | -$457.78M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$138.22M 10-Q · filed 2024-08-12 | -$255.02M 10-Q · filed 2024-08-12 | -$362.97M derived: sum of 3 quarters · filed 2025-03-03 | -$474.21M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$116.80M 10-Q · filed 2024-05-09 | -$224.75M derived: sum of 2 quarters · filed 2025-03-03 | -$335.99M derived: sum of 3 quarters · filed 2025-03-03 | -$430.57M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$107.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$219.19M derived: sum of 2 quarters · filed 2025-03-03 | -$313.77M derived: sum of 3 quarters · filed 2025-03-03 | -$417.14M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$111.24M 10-Q · filed 2023-11-09 | -$205.82M derived: sum of 2 quarters · filed 2023-11-09 | -$309.19M 10-Q · filed 2023-11-09 | -$400.79M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | -$94.58M 10-Q · filed 2023-08-08 | -$197.95M 10-Q · filed 2023-08-08 | -$289.55M derived: sum of 3 quarters · filed 2024-03-19 | -$377.96M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | -$103.37M 10-Q · filed 2023-05-11 | -$194.97M derived: sum of 2 quarters · filed 2024-03-19 | -$283.38M derived: sum of 3 quarters · filed 2024-03-19 | -$372.69M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | -$91.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$180.01M derived: sum of 2 quarters · filed 2024-03-19 | -$269.32M derived: sum of 3 quarters · filed 2024-03-19 | -$349.97M 10-K · filed 2024-03-19 |
| 2021-09-30 | -$88.41M 10-Q · filed 2022-11-09 | -$177.72M derived: sum of 2 quarters · filed 2022-11-09 | -$258.36M 10-Q · filed 2022-11-09 | -$326.69M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$89.31M 10-Q · filed 2022-08-08 | -$169.95M 10-Q · filed 2022-08-08 | -$238.28M derived: sum of 3 quarters · filed 2023-03-01 | -$304.50M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$80.64M 10-Q · filed 2022-05-10 | -$148.97M derived: sum of 2 quarters · filed 2023-03-01 | -$215.19M derived: sum of 3 quarters · filed 2023-03-01 | -$267.24M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$68.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$134.55M derived: sum of 2 quarters · filed 2023-03-01 | -$186.60M derived: sum of 3 quarters · filed 2023-03-01 | -$223.98M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$66.22M 10-Q · filed 2021-11-12 | -$118.27M derived: sum of 2 quarters · filed 2021-11-12 | -$155.65M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$52.05M 10-Q · filed 2021-08-12 | -$89.43M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$37.38M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$160.03M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |